H Tanaka, MD
Ophthalmology · San Francisco, CANPI 1285723411
Payments from drug & device makers
Across 844 payments — averaging $282.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135K
- Aerie Pharmaceuticals, Inc.$47K
- Alcon$21K
- Sight Sciences, Inc.$18K
- Glaukos Corporation$3K
- Nova Eye, Inc.$3K
- plus $10K from 24 others
Across 3 payments — averaging $7035.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$21K
What the payments were for
- Consulting fees$32,23814%
- Speaking & faculty fees$154,08165%
- Travel & lodging$22,80610%
- Food & beverage$28,57312%
- Education$500%
- Entertainment$300%
- Other$5010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 370 | $135,454 |
| Aerie Pharmaceuticals, Inc. | 83 | $47,156 |
| Alcon | 119 | $21,102 |
| Sight Sciences, Inc. | 41 | $18,340 |
| Glaukos Corporation | 35 | $3,476 |
| Nova Eye, Inc. | 3 | $3,099 |
| NEW World Medical,inc. | 23 | $2,413 |
| Oyster Point Pharma, Inc. | 22 | $1,074 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $955 |
| Rxsight Inc | 7 | $775 |
| Carl Zeiss Meditec USA, Inc. | 7 | $740 |
| Bausch & Lomb Americas Inc. | 20 | $568 |
| Mallinckrodt Hospital Products Inc. | 17 | $437 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $416 |
| Ivantis, Inc | 8 | $413 |
| Sun Pharmaceutical Industries Inc. | 13 | $388 |
| Novartis | 13 | $386 |
| Eyepoint US, Inc. | 8 | $325 |
| Carl Zeiss Meditec, Inc. | 3 | $153 |
| Thea Pharma Inc. | 6 | $139 |
| Harrow Eye, LLC | 4 | $125 |
| Tarsus Pharmaceuticals, Inc. | 4 | $96 |
| ANI Pharmaceuticals, Inc. | 1 | $45 |
| Kala Pharmaceuticals, Inc. | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $36 |
| Omeros Corporation | 2 | $31 |
| Optos, Inc. | 1 | $30 |
| Dompe US, Inc. | 1 | $27 |
| Beaver-visitec International, Inc. | 1 | $26 |
| Alcon Research LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$61,166
- Rhopressa$56,960
- XEN GLAUCOMA TREATMENT SYSTEM$52,559
- DURYSTA$47,132
- XEN$27,755
- SIMBRINZA$14,433
- OMNI(R) SURGICAL SYSTEM (US)$12,021
- OMNI$5,634
- Ahmed Glaucoma Valve$1,936
- Kahook Dual Blade$1,936
- TYRVAYA$759
- Hydrus Microstent$756
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$650
- VYZULTA$625
- LUMERA$501
- RXSIGHT INJECTOR HANDPIECE$461
- RXSIGHT CONTACT LENS$461
- RXSIGHT INJECTOR CARTRIDGE$461
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$461
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$461
How this compares
$238,279 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 141 | $71,422 |
| RocklatanNetarsudil Mesylat/Latanoprost | 120 | $66,934 |
| VyzultaLatanoprostene Bunod | 99 | $52,786 |
| LumiganBimatoprost | 89 | $45,226 |
| RestasisCyclosporine | 50 | $34,707 |
| CombiganBrimonidine Tartrate/Timolol | 63 | $27,243 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 95 | $19,144 |
| Restasis MultidoseCyclosporine | 15 | $16,715 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 61 | $16,228 |
| Cyclosporine | 32 | $12,283 |
| Alphagan PBrimonidine Tartrate | 27 | $11,221 |
| Prednisolone Acetate | 314 | $9,483 |
| AzoptBrinzolamide | 20 | $7,911 |
| Brimonidine Tartrate | 123 | $7,318 |
| Brinzolamide | 42 | $6,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $47,156 | $138,355261 claims |
| AbbVieLumigan, Restasis, Combigan, Restasis Multidose, Alphagan P | $135,454 | $135,112244 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $568 | $52,78699 claims |
| AlconSimbrinza, Azopt | $21,102 | $24,13881 claims |
| NovartisTravatan Z | $386 | $6,38113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Francisco
- Nisha AcharyaSan Francisco$33M
- Daniel SchwartzSan Francisco$8M
- Robert BhisitkulSan Francisco$778K
- Gaurav ShahSan Francisco$620K
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.